KV Pharmaceutical and Sandoz cough/cold product
Executive Summary
Long-term licensing agreement concluded for a once-daily cough/cold drug administered through KV's delivery technology KV/24. Cash payments, royalties and manufacturing revenues will be provided to KV. Other recent licensing agreements for KV include one with SS Pharmaceutical of Japan for Liquette stomach remedy developed by KV ("The Pink Sheet" Aug. 10, "In Brief") and with Taisho Pharmaceutical Ltd. of Japan for a once-a-day version of Japan's number one marketed cough/cold product ("The Pink Sheet" Oct. 5, "In Brief").
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.